Alaunos reports ALN1003 preclinical liver-weight finding after body-fat adjustment in DIO mouse study

Alaunos Therapeutics, Inc.

48-day DIO mouse study: ALN1003-treated animals had lower liver weight after adjusting for body fat (ANCOVA p=0.000005; HC3 robust p=0.000015).
Liver-weight finding consistent with lower liver injury enzymes (ALT, AST, ALP) and lower mean NAS score (2.7 vs 5.0 for selected controls).
HOMA-IR remained significant after adjusting for body fat (ANCOVA p=0.0006; HC3 p=0.0014).
Favorable adipose biomarkers: lower leptin, higher adiponectin, higher adiponectin-to-leptin ratio in DIO Study 1.
ALN1003 is non-hormonal, non-incretin small molecule; all data from non-GLP mouse studies, may not translate to humans.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.